| __timestamp | Neurocrine Biosciences, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 7751000 |
| Thursday, January 1, 2015 | 32480000 | 10251000 |
| Friday, January 1, 2016 | 68081000 | 9575000 |
| Sunday, January 1, 2017 | 169906000 | 10912000 |
| Monday, January 1, 2018 | 248932000 | 11049000 |
| Tuesday, January 1, 2019 | 354100000 | 11646000 |
| Wednesday, January 1, 2020 | 433300000 | 13265000 |
| Friday, January 1, 2021 | 583300000 | 25805000 |
| Saturday, January 1, 2022 | 752700000 | 35182000 |
| Sunday, January 1, 2023 | 887600000 | 94999000 |
| Monday, January 1, 2024 | 1007200000 |
Unlocking the unknown
In the competitive world of biotechnology, managing expenses is crucial for success. This chart highlights the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Viridian Therapeutics, Inc. over the past decade. Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, Viridian Therapeutics has maintained a more modest growth, with expenses increasing by approximately 12 times over the same period.
This comparison offers a fascinating glimpse into how two companies navigate financial strategies in the biotech sector.
Who Optimizes SG&A Costs Better? Sanofi or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: GSK plc vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?